These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 820422)

  • 1. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
    Legha SS; Slavik M; Carter SK
    Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
    Kardinal CG; Luce JK
    Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
    Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
    Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexamethylmelamine and pentamethylmelamine: an update.
    Hahn DA
    Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
    Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
    Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
    Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
    Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
    [No Abstract]   [Full Text] [Related]  

  • 7. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
    Stehman FB; Ehrlich CE; Callangan MF
    Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
    Denefrio JM; Vogel CL
    Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I trial of pentamethylmelamine.
    Ajani JA; Cabanillas FF; Bodey GP
    Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of hexamethylmelamine in advanced ovarian carcinoma treatment.
    Weiss RB
    Gynecol Oncol; 1981 Oct; 12(2 Pt 1):141-9. PubMed ID: 6795094
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination chemotherapy with CCNU (NSC-79037),hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in advanced bronchogenic carcinoma.
    DiBella NJ; Nelson RA; Norgard MJ
    Oncology; 1975; 32(2):82-5. PubMed ID: 815858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.
    Wharton JT; Rutledge F; Smith JP; Herson J; Hodge MP
    Am J Obstet Gynecol; 1979 Apr; 133(7):833-44. PubMed ID: 219695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexamethylmelamine as a single second-line agent in ovarian cancer.
    Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
    Gynecol Oncol; 1990 Jan; 36(1):93-6. PubMed ID: 2104819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
    Van Amburg AL; Presant CA; Vélez-García E; Klahr C
    Cancer Treat Rep; 1979 Jan; 63(1):141-2. PubMed ID: 105806
    [No Abstract]   [Full Text] [Related]  

  • 15. cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
    Lund B; Aabo K; Rørth M; Hansen HH
    Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1089-92. PubMed ID: 6819145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
    Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
    Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.
    Legha SS; Buzdar AU; Hortobagyi GN; DiStefano A; Wiseman CL; Yap HY; Blumenschein GR; Bodey GP
    Cancer Treat Rep; 1979; 63(11-12):2053-6. PubMed ID: 118805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
    Fabian CJ; Rasmussen S; Stephens R; Haut A; Smith F; Balcerzak S; Tranum B
    Cancer Treat Rep; 1979 Aug; 63(8):1359-61. PubMed ID: 113095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexamethylmelamine: activity in lymphoma and other tumors.
    Macdonald JS
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():99-102. PubMed ID: 1904314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of small cell carcinoma of the lung with hexamethylmelamine.
    Huang MN; Takita H; Catane H; Yee Chen T
    Oncology; 1978; 35(1):29-32. PubMed ID: 203884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.